Description of Material. This chapter describes the details of the technology transfer material includ- ing those for general purpose of technology transfer as described in Section 2.1 and domain-specific material as described in Section 2.2.
Description of Material. Material consists of specific files and data that have been ordered from Licensor. Some or all of the Material may not be available at certain times due to maintenance and/or computer, telecommunication, electrical or network failure or any other reasons beyond our control, such as acts of god, terrorism, etc. Licensor shall not be liable to you if you are unable to gain access to the system.
Description of Material. Note: Please provide us with a brief description of the material being transferred. If one has been compiled, the material should be accompanied by the catalogue/inventory/arrangement system (where applicable). Information about the history of the material can be provided under point 3 below. Description of material: Quantity of material: Express quantities in the most appropriate measure, e.g. 2 linear metres / 5 file boxes etc. Format of material: I.e. the physical format of the material e.g. paper records, books, photographs, DVDs, slides etc. Inventory/catalogue attached? (Yes/No):
Description of Material. For the purpose of this transfer agreement, the term Material is defined as [Describe here the Material which will be transmitted], including the documentation and information as further specified in clause 3.
Description of Material. ANNEX 2 Any publication of the results of the research shall acknowledge the source of the Materials: “We thank the Wellcome Sanger Institute and its funders for providing the mutant mouse line (Allele:[state allele]), and INFRAFRONTIER/XXXX (xxx.xxxxxxxxxxxxx.xx) partner [insert XXXX partner] from which the mouse was received. Funding information may be found at xxx.xxxxxx.xx.xx/xxxxxxxxxxx and associated primary phenotypic information at xxx.xxxxxxxxxxxxxx.xxx.” Details of the alleles have been published, please include the following references in publications: Xxxxx, X. X., Xxxxxx, A.-K., Xxxx, X. X., Xxxxx, X., Xxxxxx, M., Xxxxxxx, X. X., Xxxxxxxxx, X., et al. (2013). Genome- wide Generation and Systematic Phenotyping of Knockout Mice Reveals New Roles for Many Genes. Cell, 154(2), 452–464. Xxxxxxx, X.X., Xxxxx, B., Xxxx, A.P., Xxxxxxxxxxxx, M., Xxxxxxx, X., Xxxx, V., Xxxxxx, A.O., Xxxxxx, X., Xxxxxx, X., Xxx, X. et al. (2011) A conditional knockout resource for the genome-wide study of mouse gene function. Nature, 474, 337-342. Xxxxxxx A, Anastassiadis K, Xxxxx A, Xxxxxx XX, Xxxx C, Xxxxxxx M-C, Xxxxxxxxx J, Xxxxx
Description of Material. Identify the people and places/events depicted; indicate if unknown. Use space below and additional pages if necessary. Please be elaborate, we may have to rely solely on your information to identify these photographs. Please try to give us as much of the requested information as possible: Name and address of photographer: Place: Date of photograph: Event:
Description of Material. Purpose and usage Location The Material will be transferred to the Recipient and used at: Restrictions Period Commercialization of rights Responsibilities Liability Warranty Termination of MTA Publications
Description of Material. Material is divided into three categories: (a) reference samples, (b) previously released GMP clinical batches (including drug substance, bulk and unlabeled primary packed drug product, and clinical bulk product), and (c) stability samples and other items on Exhibit F. Novartis represents and warrants that, as of the release date, clinical study (i.e., drug substance and bulk product) Material (and not the reference samples and other items) was manufactured in accordance with Laws (including GMP) and meets applicable specifications. Novartis shall provide or arrange to be provided to Erasca documentation signed by an authorized representative of Novartis, certifying that such clinical study Material was manufactured in accordance with its specifications and all Law, including GMP, and that such Material meets applicable specifications. No such representation or warranty is given with respect to any changes to Law following the respective release date of such clinical study Material. Except as provided in this Section 5.8.1, any Material transferred to Erasca pursuant to this Agreement is provided “as is” and “where is”, and without representation or warranty of any kind, and Novartis hereby expressly disclaims any and all other warranties with respect to such Material, including any implied warranties of merchantability and fitness for a particular purpose.
Description of Material. BGJ398 Material is divided into three categories: reference samples, non-GMP technical batches, and previously released GMP clinical batches (see Exhibit D). Novartis represents and warrants that released clinical study BGJ398 Material (and not the non-GMP technical batches or reference samples) was manufactured in accordance with Applicable Laws (including GMP) where the relevant study was to be conducted at the time of release and QED shall be provided with documentation signed by an authorized representative of Novartis, certifying that such BGJ398 Material was manufactured in accordance with its specifications and all Applicable Law, including GMP; no such representation or warranty is given with respect to the Applicable Law of any other country or jurisdiction or to any changes to Applicable Law following the release date. Except as provided above, the BGJ398 Material is provided “as is” and “where is”, and without representation or warranty of any kind. [***] Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.
Description of Material. Material is divided into four categories: (a) reference samples, (b) non-GMP technical batches, (c) previously released GMP clinical batches (including drug substance, bulk and unlabeled primary packed drug product, and clinical bulk product), and (d) stability samples and other items on Exhibit F. Novartis represents and warrants that, as of the release date, clinical study (i.e., drug substance and bulk product) Material (and not the non-GMP technical batches or reference samples and other items) was manufactured in accordance with Applicable Laws (including GMP). Novartis shall provide or arrange to be provided to Ideaya documentation signed by an authorized representative of Novartis, certifying that such Material was manufactured in accordance with its specifications and all Applicable Law, including GMP. No such representation or warranty is given with respect to any changes to Applicable Law following the respective release date of such clinical study Material. Except as provided in this Section 6.2 and Section 13, any Material transferred to Ideaya pursuant to this Agreement is provided “as is” and “where is”, and without representation or warranty of any kind, and Novartis hereby expressly disclaims any and all other warranties with respect to such Material, including any implied warranties of merchantability and fitness for a particular purpose.
